Grant: Discovery Grants Program - Individual
University of Toronto
$60,000.00
A Discovery Toolbox: Machine Learning Guided Design and the Automated Cell-Free Manufacture of Proteins.
FY 2024-25
Summary
Proposal. Leveraging over nine years of interdisciplinary research, here we propose the development of i) an in silico protein design platform and ii) automated, cell-free biomanufacturing to, ultimately, improve patient access to biologic therapeutics.
Background. Proteins can be thought of as the pointy end of the genome, representing biology's toolbox in the form of enzymes, antibodies, growth factors, among many others. Not surprisingly, proteins themselves are an important class of therapeutics, such as the anti-TNF? antibody Humira ($20B/y), and are broadly enabling to biotechnology-based industry. Despite the importance of proteins in Pharma and Biotech, protein discovery and manufacturing remain a highly specialized domain and has not seen the barrier to entry fall as has occurred with synthetic DNA. This translates to slower innovation with knock-on effects for the rate of therapeutic innovation.
By combining cell-free synthesis (CFS) with automation, we propose that biomanufacturing can be distributed to enable widespread and affordable researcher access to custom and reagent proteins (e.g. antibodies). Ultimately, and perhaps more critically, the technology holds the promise of enabling the rapid on-site production of vaccines and countermeasures, bolstering resilience of northern communities and the military to biothreats. The proposal is firmly planted on the engineering and technology development aspects of this research challenge. Here we propose three objectives aimed at improving the rate of protein discovery, access to the tools of discovery, and the resulting therapeutics.
AIM I. In silico and cell-free discovery platform for protein. Here using massively parallel, droplet-based cell-free protein expression, we will generate the labelled data (sequence + function) need for rapid, in silico design new of therapeutic peptides and proteins.
AIM II. Automated cell-free synthesis of proteins for research applications. The rate of research globally is slowed by access to timely and inexpensive reagents. Here we will extend the capabilities of our Mango device toward automated production of several protein reagent classes.
AIM III. Development of automated portable therapeutic biomanufacturing for remote and low-resource settings (northern communities, military). Here, we will augment the Mango device with capacity for on-site GMP therapeutic production, quality control and product validation.
ANTICIPATED OUTCOMES. With the support of the NSERC Discovery Grant program, this project will contribute improving Canadian's access to biotechnology. Such access will contribute to revolutionizing human health and agriculture, creating new industries and economic prosperity, and ensuring resilience to biological threats. The vast scale and remote communities of Canada make such technologies crucial, and leadership in the technology development will position Canada well in what many expect to be, the century of biology.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2023-04906
Name nom
Pardee, Keith
Department département
Faculty of Pharmacy
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
60000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
A Discovery Toolbox: Machine Learning Guided Design and the Automated Cell-Free Manufacture of Proteins.
Keywords
synthetic biology; peptide/protein engineering; biologic therapeutics; computational design; cell-free protein expression; droplet microfluidics; countermeasures; chemical biological sensors
Application summary
Proposal. Leveraging over nine years of interdisciplinary research, here we propose the development of i) an in silico protein design platform and ii) automated, cell-free biomanufacturing to, ultimately, improve patient access to biologic therapeutics.
Background. Proteins can be thought of as the pointy end of the genome, representing biology's toolbox in the form of enzymes, antibodies, growth factors, among many others. Not surprisingly, proteins themselves are an important class of therapeutics, such as the anti-TNF? antibody Humira ($20B/y), and are broadly enabling to biotechnology-based industry. Despite the importance of proteins in Pharma and Biotech, protein discovery and manufacturing remain a highly specialized domain and has not seen the barrier to entry fall as has occurred with synthetic DNA. This translates to slower innovation with knock-on effects for the rate of therapeutic innovation.
By combining cell-free synthesis (CFS) with automation, we propose that biomanufacturing can be distributed to enable widespread and affordable researcher access to custom and reagent proteins (e.g. antibodies). Ultimately, and perhaps more critically, the technology holds the promise of enabling the rapid on-site production of vaccines and countermeasures, bolstering resilience of northern communities and the military to biothreats. The proposal is firmly planted on the engineering and technology development aspects of this research challenge. Here we propose three objectives aimed at improving the rate of protein discovery, access to the tools of discovery, and the resulting therapeutics.
AIM I. In silico and cell-free discovery platform for protein. Here using massively parallel, droplet-based cell-free protein expression, we will generate the labelled data (sequence + function) need for rapid, in silico design new of therapeutic peptides and proteins.
AIM II. Automated cell-free synthesis of proteins for research applications. The rate of research globally is slowed by access to timely and inexpensive reagents. Here we will extend the capabilities of our Mango device toward automated production of several protein reagent classes.
AIM III. Development of automated portable therapeutic biomanufacturing for remote and low-resource settings (northern communities, military). Here, we will augment the Mango device with capacity for on-site GMP therapeutic production, quality control and product validation.
ANTICIPATED OUTCOMES. With the support of the NSERC Discovery Grant program, this project will contribute improving Canadian's access to biotechnology. Such access will contribute to revolutionizing human health and agriculture, creating new industries and economic prosperity, and ensuring resilience to biological threats. The vast scale and remote communities of Canada make such technologies crucial, and leadership in the technology development will position Canada well in what many expect to be, the century of biology.